Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Source: View publication →
In a phase 1 trial, a single dose of the novel long-acting siRNA Kylo-11 was well-tolerated and produced exceptionally deep, durable reductions in lipoprotein(a) of up to 97% over 48 weeks.
Key Findings
Study Design
Study Limitations
Clinical Significance
Kylo-11's unique non-canonical architecture (featuring four GalNAc moieties across two strands) enables an unusually prolonged and potent pharmacodynamic effect. Maintaining a ~95% reduction in Lp(a) for nearly a year after a single dose suggests the viability of an annual dosing regimen, which could dramatically improve patient adherence and logistical feasibility in managing this untreatable genetic cardiovascular risk factor.
Historical Context
Lipoprotein(a) is a highly heritable, causal risk factor for atherosclerotic cardiovascular disease that is largely unresponsive to diet, exercise, and standard lipid-lowering therapies like statins. While several RNA interference (RNAi) and antisense therapies (e.g., pelacarsen, olpasiran, lepodisiran) have recently advanced in clinical trials to inhibit hepatic Lp(a) production, Kylo-11 was designed with a novel 'dual-site' delivery structure to maximize liver uptake and radically extend its duration of action, aiming for a once-yearly treatment model.
Guided Discussion
High-yield insights from every perspective
Lipoprotein(a) is highly atherogenic and prothrombotic. What is the structural basis for its prothrombotic nature, and how does an siRNA like Kylo-11 disrupt its synthesis at the cellular level?
Key Response
Tests knowledge of apolipoprotein(a), which shares high structural homology with plasminogen, thereby competitively inhibiting fibrinolysis. siRNA therapies like Kylo-11 work by entering the hepatocyte, integrating into the RNA-induced silencing complex (RISC), and binding to the mRNA of the LPA gene, leading to its cleavage and preventing translation of the apo(a) protein.
Current lipid management focuses heavily on LDL-C. In what clinical scenarios should a patient's Lipoprotein(a) be measured, and why is the profound reduction seen with Kylo-11 clinically relevant despite optimal statin therapy?
Key Response
Guidelines recommend checking Lp(a) at least once in an adult's lifetime, especially in those with premature ASCVD, a family history of premature ASCVD, or familial hypercholesterolemia. It is clinically relevant because statins do not lower Lp(a) and can sometimes slightly increase it, leaving patients with high Lp(a) at significant residual risk for ASCVD and calcific aortic valve stenosis.
Kylo-11 is described as a non-canonical siRNA demonstrating sustained Lp(a) reduction of up to 97 percent at 48 weeks after a single dose. How does its pharmacokinetic profile and mechanism of durability compare to other RNA-targeted therapies in development for Lp(a), such as olpasiran or pelacarsen?
Key Response
Pelacarsen is an antisense oligonucleotide (ASO) requiring relatively frequent dosing as it is consumed in the RNase H-mediated degradation process. In contrast, siRNAs like olpasiran and Kylo-11 utilize the RISC complex, which is catalytic and recycles, allowing for much longer durations of action. Kylo-11's non-canonical modifications likely enhance its stability and RISC retention, pushing the dosing interval to potentially once a year.
With Kylo-11 demonstrating a 48-week duration of effect from a single dose, we are moving toward an annual injection model for lipid management. How might this paradigm shift alter patient adherence, clinical workflow, and the shared decision-making process for cardiovascular risk reduction?
Key Response
An annual injectable therapy effectively eliminates daily non-adherence, a major barrier in lipid management. However, it shifts the burden from patient compliance to healthcare system infrastructure, requiring reliable recall systems, injection clinic workflows, and robust pre-treatment counseling since an ultra-long-acting drug cannot be easily withdrawn if adverse effects occur.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In evaluating a novel ultra-long-acting siRNA like Kylo-11 in a Phase 1 first-in-human trial, what are the primary pharmacokinetic and safety monitoring challenges, particularly regarding the reversibility of off-target effects over a 48-week observation period?
Key Response
The primary challenge is the lack of an 'off-switch.' If off-target gene silencing or hepatotoxicity occurs, the drug's extended half-life in the liver cannot be easily reversed. Phase 1 trials must therefore employ highly staggered dose-escalation cohorts, exceptionally long follow-up periods, and rigorous transcriptomic and biomarker monitoring to ensure that any delayed or cumulative toxicities are captured.
While the 97 percent reduction in Lp(a) at 48 weeks is striking, this Phase 1 trial relies entirely on a surrogate biomarker. As an editor evaluating this for publication, what specific safety signals and trial design elements must be scrutinized to ensure this profound, prolonged target knockdown translates safely into larger trials?
Key Response
Editors must scrutinize liver function tests, injection site reactions, and platelet counts, as these are known class effects of RNAi therapies. Furthermore, they must flag the small sample size and healthy volunteer demographic typical of Phase 1, emphasizing that profound biomarker reduction does not guarantee cardiovascular event reduction, which necessitates massive Phase 3 cardiovascular outcome trials (CVOTs).
Current ACC/AHA and ESC guidelines recommend measuring Lp(a) at least once in an adult's lifetime but lack specific pharmacological recommendations due to the absence of approved targeted therapies. If Phase 3 trials confirm Kylo-11's efficacy, what evidentiary thresholds regarding absolute risk reduction would be required to upgrade Lp(a)-lowering to a Class 1 recommendation?
Key Response
Currently, Lp(a) is considered a risk-enhancing factor to favor statin initiation (ACC/AHA Class 2a). For Kylo-11 to achieve a Class 1 recommendation for ASCVD risk reduction, Phase 3 outcome trials must demonstrate a statistically significant and clinically meaningful reduction in major adverse cardiovascular events (MACE) in a well-defined high-risk population, proving that the absolute risk reduction outweighs the costs and long-term safety risks of novel gene-silencing therapy.
Clinical Landscape
Noteworthy Related Trials
Pelacarsen Phase 2 Trial
Tested
Pelacarsen (antisense oligonucleotide)
Population
Patients with established cardiovascular disease and elevated Lp(a)
Comparator
Placebo
Endpoint
Percent change in Lp(a) level at 6 months
OCEAN(a)-DOSE Trial
Tested
Olpasiran (siRNA) at various doses
Population
Patients with ASCVD and Lp(a) >150 nmol/L
Comparator
Placebo
Endpoint
Percent change in Lp(a) concentration at 36 weeks
Lepodisiran Phase 1 Trial
Tested
Lepodisiran (short interfering RNA)
Population
Adults without cardiovascular disease but with elevated Lp(a) levels
Comparator
Placebo
Endpoint
Safety, tolerability, and change in Lp(a) concentration over 336 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis